DelveInsight’s, “Cold Agglutinin Disease Pipeline Insight, 2023,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in the Cold Agglutinin Disease pipeline landscape. It covers the Cold Agglutinin Disease pipeline drug profiles, including Cold Agglutinin Disease clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
For Cold Agglutinin Disease Emerging drugs, the Cold Agglutinin Disease pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Cold Agglutinin Disease pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
In the Cold Agglutinin Disease Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Cold Agglutinin Disease clinical trials studies, Cold Agglutinin Disease NDA approvals (if any), and product development activities comprising the technology, Cold Agglutinin Disease collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Key takeaways from the Cold Agglutinin Disease Pipeline Report
Request a sample and discover the recent breakthroughs happening in the Cold Agglutinin Disease Pipeline landscape @ Cold Agglutinin Disease Pipeline Outlook Report
Cold Agglutinin Disease Overview
Cold agglutinin disease (CAD) is a rare autoimmune disorder characterized by the premature destruction of red blood cells (hemolysis). Autoimmune diseases occur when one’s own immune system attacks healthy tissue. More specifically, CAD is a subtype of autoimmune hemolytic anemia. In this type of disorder, red blood cells are “tagged” by antibodies and are then destroyed by other types of immune cells. The disease is termed “cold” because the antibodies are active and cause hemolysis at cold temperatures, usually 3 to 4oC (37 to 39oF), which is not necessarily the case in other types of autoimmune hemolytic anemia.
Cold Agglutinin Disease Emerging Drugs Profile
BIVV020 is a humanized monoclonal antibody that targets complement C1s. A phase 1b clinical trial that was testing the safety and tolerability of the experimental drug BIVV020 in adult patients with cold agglutinin disease (CAD) has been completed. The primary objective of the trial was to assess the safety and tolerability of the treatment as measured by the number of participants with adverse events. Secondary objectives were the effect of the treatment on complement-mediated hemolysis, as well as its pharmacodynamics, pharmacokinetics, and immunogenicity. The drug is being developed by Bioverativ, a Sanofi company.
Iptacopan is an oral investigational therapy by Novartis. It is a first-in-class, potent, and highly selective factor B inhibitor of the alternative complement pathway. It binds to factor B and suppresses the activity of C3 convertase. This way, signaling from the alternative complement pathway and the activation of the amplification loop are also suppressed. This inhibits the generation of the downstream C5 convertase complex, opsonization, and the formation of C3a and C5a anaphylatoxins and membrane attack complex. Because the direct classical and lectin pathway signaling remains intact, the risk of meningococcal infection is lower with Iptacopan compared to terminal complement pathway inhibitors. Currently, the drug is in Phase II stage of Clinical trial evaluation for the treatment of Cold Agglutinin Disease.
For further information, refer to the detailed Cold Agglutinin Disease Drugs Launch, Cold Agglutinin Disease Developmental Activities, and Cold Agglutinin Disease News, click here for Cold Agglutinin Disease Ongoing Clinical Trial Analysis
Cold Agglutinin Disease Pipeline Therapeutics Assessment
There are approx. 5+ key companies which are developing the therapies for Cold Agglutinin Disease. The companies which have their Cold Agglutinin Disease drug candidates in the most advanced stage, i.e. phase II include, Novartis Pharmaceuticals.
Cold Agglutinin Disease Pipeline Segmentation
Phases
Route of Administration
Molecule Type
Find out more about the Cold Agglutinin Disease Pipeline Segmentation, Therapeutics Assessment, and Cold Agglutinin Disease Emerging Drugs @ Cold Agglutinin Disease Treatment Landscape
Scope of the Cold Agglutinin Disease Pipeline Report
Dive deep into rich insights for drugs for Cold Agglutinin Disease Pipeline Companies and Therapies, click here @ Cold Agglutinin Disease Unmet Needs and Analyst Views
Table of Content
Got Queries? Find out the related information on Cold Agglutinin Disease Mergers and acquisitions, Cold Agglutinin Disease Licensing Activities @ Cold Agglutinin Disease Recent Trends, and Future Perspectives
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/